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Summary 
Background:  In Asian countries with limited resources, clarithromycin-based triple 
therapy may not be readily available. There is also limited data on direct comparison 
of different regimes in Asia. 
Aim:  To compare two lansoprazole-based non-clarithromycin triple therapy and one 
dual therapy in a prospective double-blind placebo-controlled study on the efficacy of 
Helicobacter pylori eradication and duodenal ulcer healing. 
Methods: Fourteen centers in Asia participated in this study. Patients with acute 
duodenal ulcer and were H. pylori positive were recruited. They were randomized to 
receive: A) lansoprazole 30mg bid, amoxycillin 1 g  bid and metronidazole 500mg 
bid for two weeks (LAM-2W), or B) LAM for one week and placebo (LAM-1W) , or  
C) LA and placebo for two weeks (LA). Upper endoscopy was repeated at week 6 to 
check for duodenal ulcer healing. Symptoms and side effects were recorded. 
Results: A total of 228 patients were recruited, and two patients took less than 50% of 
the drugs. H. pylori eradication rates (intention to treat) were 68/82 (83%) with LAM-
2W, 55/71 (78%) with LAM-1W and 43/75 (57%) with LA. There were significant 
differences (p=0.001) in eradication rates when comparing either LAM-2W or LAM-
1W with LA. The eradication rate in patients with metronidazole resistant H. pylori 
strains were significantly lower than those with metronidazole sensitive strains 
(P=0.0001). The duodenal ulcer healing rates at week 6 were 85%, 85% and 72% in 
LAM-2W, LAM-1W and LA respectively (p=0.065). Side effects occurred in 13%, 
11% and 9% in LAM-2W, LAM-1W and LA respectively. H pylori eradication and 
initial ulcer size were factors affecting duodenal ulcer healing. 
Conclusions: This Asian multi-center study showed that one week lansoprazole-based 
triple therapy without clarithromycin has similar efficacy in H. pylori eradication and 
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ulcer healing compared with two week regime. Both triple therapies were 
significantly better than dual therapy in H. pylori eradication. Therefore one week 
lansoprazole-based triple therapy is as safe and effective as two week therapy in 
eradication of H. pylori infection and healing of duodenal ulcer in these Asian 
centers. 
 
 
 
 
 
Key words:  Helicobacter pylori, duodenal ulcer, therapy, Asia.
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Introduction 
The Asian Pacific Consensus meeting has recommended the use of triple therapy as a 
standard in the treatment of Helicobacter pylori  related duodenal ulcer diseases in 
Asian countries (1). The recommendation included the use of a proton-pump inhibitor 
together with clarithromycin and either amoxycillin or metronidazole. This regime is 
much more expensive than the classical triple therapy consisting of bismuth, 
metronidazole and tetracycline. In parts of Asia where clarithromycin is not readily 
available for financial or other reasons, an alternative regime with proven efficacy in 
H. pylori eradication and ulcer healing is needed. On the other hand, metronidazole 
resistance is a major problem in some Asian countries and this may potentially affect 
the result of metronidazole containing regimes. The aim of this study was to evaluate 
two lansoprazole-based triple therapy and one dual therapy without clarithromycin for 
curing of H. pylori infection and healing of duodenal ulcer.  
  
Materials and Methods 
 Patients aged between 18-80 years inclusive, with active duodenal ulcer of at 
least 5mm in diameter who were H. pylori positive (as determined by at least two 
positive results from CLO test(Delta West, Bentley, West Australia), histology and 
culture ) were invited to participate in the study. Patients were excluded if they had 
acute ulcer bleeding, previous gastric or duodenal surgery, underlying malignant 
conditions, allergy to proton pump inhibitors or amoxycillin or metronidazole, been 
on treatment with bismuth compounds and/or antibiotics for the last 4 weeks before 
study, regular intake of nonsteroidal antiinflammatory drugs for the last 4 weeks 
before study, regular intake of proton-pump inhibitors or H2-receptor antagonists for 
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the past 2 weeks before study, history of bleeding tendency, or had significant 
gastrointestinal, renal , hepatic, cardiovascular, metabolic or hematological disease. 
 The study consisted of a double-blind, prospective randomized, placebo-
controlled multicentre study carried out between July 1996 and June 1998 in 14 
hospitals in Hong Kong, China, Indonesia, the Philippines, Singapore and Thailand. 
Randomization was performed individually in the 14 centers by drawing the code 
(Group A, B or C) from an envelope. The code was placed back to the envelope after 
the draw. The study was approved by the local Ethics Committee at each participating 
centre and written informed consent was obtained from patients before entering the 
study. 
 
Treatment 
 Patients were randomized to one of the following three regimes: a) 
lansoprazole 30mg bid plus amoxycillin 1 g bid plus metronidazole 500mg bid all for 
two weeks (LAM-2W); b) lansoprazole 30mg bid plus amoxycillin 1 g bid plus 
metronidazole 500mg bid all for one week with three placebos for another week 
(LAM-1W); or c) lansoprazole 30mg bid plus amoxycillin 1 g bid for two weeks with 
metronidazole placebo for two weeks (LA-2W). All medication was taken each day.  
 
Follow up 
 Patients returned at week 6 to return the symptom diary and bottles for drug 
count. They were also asked for presence of adverse events. Endoscopy was 
performed on that day to check for ulcer healing. The duodenal ulcer was defined as 
healed when there was complete epithelialization of ulcer site; partially healed when 
the size of ulcer is reduced by over 50%; and not healed when the ulcer size is 
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reduced by less than 50%. During endoscopy, two antral and one corpus biopsy were 
used for CLO test; two antral and two corpus biopsies were sent for histology, and 
one antral biopsy was sent for culture test at week 0. 13C urea breath test were also 
performed in all patients, as detailed below. All biopsies for histology were sent to the 
Department of Pathology, Queen Mary Hospital, Hong Kong for examination of 
presence of H. pylori by a single pathologist (JH). Patients were considered H. pylori 
negative at week 6 if the results of all three tests were negative. 
 
13C-urea breath test 
A 13C-urea breath test for the detection of H pylori infection was performed on all 
patients at week 6. Briefly, after an overnight fast, a breath sample was collected in a 
sterile vacutainer 5 minutes after drinking a standard test meal for delay gastric 
emptying. The patient then took a test drink containing 75 mg 13C-urea dissolved in 
50 ml water, and underwent various simple postural positioning maneuvers to allow 
contact of the solution with the various parts of the stomach. A second breath sample 
was collected 30 minutes after the drink. The results of the breath test theoretically, 
therefore, represented the H. pylori status of the stomach as a whole. All breath 
samples were then sent to the Simon KY Lee Digestive Disease Laboratory, Queen 
Mary Hospital, University of Hong Kong, Hong Kong and analyzed with a purpose 
designed isotope ratio mass spectrometer (Fison Instruments, UK). A delta value of 
greater than 5 0/00 was considered positive for H. pylori infection. The results of the 
breath tests were not disclosed to the investigators, including the research nurses and 
endoscopists. 
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Bacterial culture 
Antral biopsies were obtained from patients at week 0 and were totally embedded into 
Stuart transport medium (Oxoid, U.K.), stored at 40C and sent to the regional 
microbiology laboratories within two hours. Culture was performed using Columbia 
blood agar with 7% horse blood and incubated at 370C under microaerophilic 
condition (5% CO2). H. pylori colonies were confirmed by positive urease, oxidase 
and catalase test together with the identification of Gram negative spiral looking 
organism on microscopy. Metronidazole susceptibility was determined by modified 
Kirby-Bauer disc diffusion procedure. An inhibition zone diameter of > 15 mm is 
regarded as metronidazole susceptible. 
 
 
Statistical Analysis 
 To confirm a homogeneity of three treatment groups, patient characteristics 
were compared with chi-square test for the categorical data, Kruskal-Wallis test for 
ranking data and analysis of variance for quantitative data. The per protocol and 
intention to treat populations were included in the efficacy analyses. The per protocol 
population included only those eligible patients who had undergone an upper 
endoscopy with testing of H. pylori status and had taken at least 50% of the study 
medication. The intention to treat population included all evaluable patients who had 
taken at least one dose of study medication. Eradication rates, ulcer healing rates and 
adverse event rates of the groups were compared based on a closed testing procedure. 
That is if a statistically significant difference was detected with chi-square test among 
the three groups, pair wise comparisons were carried out, using the chi-square test 
without correction of continuity. The 14 institutions were grouped into 6 regions 
 7
geographically, namely South China (Hong Kong and Guangdong); North China; 
Indonesia; the Philippines; Singapore; and Thailand.  P-values of < 0.05 were 
considered significant. In order to evaluate factors that may affect duodenal ulcer 
healing at week 6, logistic regression analysis was performed, with results expressed 
as odds ratios and 95% confidence interval.   
 
 
Results 
 Two hundred and twenty eight patients with uncomplicated active duodenal 
ulcers at endoscopy fulfilling the inclusion and exclusion criteria were enrolled in the 
study.  The mean age of these patients was 47.5 years (range 18 to 80 yrs ). Eighty 
two patients were randomized to receive treatment under LAM-2W; seventy one 
patients received treatment under LAM-1W and seventy five patients received 
treatment under LA. These patients’ data was all included in the intent-to-treat 
analysis.  Two patients in LA did not finish more than 50% of the drugs, was 
classified as non-compliance and excluded from the per protocol analysis.  The 
demographic data and endoscopic findings were summarized in Table 1. 
 
 
H. pylori  eradication 
 According to the intent-to-treat analysis at week 6, H. pylori eradication was 
achieved in 68 patients (82.9%), 55 patients (77.5%) and 43 patients (57.3%) in 
LAM-2W, LAM-1W and LA respectively (P=0.001).  For the per protocol analysis, 
H. pylori eradication was achieved in 68 patients (82.9%), 55 patients (77.5%) and 43 
patients (58.9%) in LAM-2W, LAM-1W and LA respectively (P=0.002). In both 
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intention-to-treat and per protocol analysis, the eradication rates of two week triple 
therapy were significantly better than that of dual therapy with p-value of 0.0008 and 
0.0012 respectively.  Similarly, the eradication rates of one week triple therapy in 
both intention-to-treat and per protocol analysis were significantly better than that of 
dual therapy with p-value of 0.01 and 0.02 respectively. But there was no significant 
difference in the eradication rates between both triple therapy regimes. (Table 2) 
 
 
Metronidazole resistance 
 Results of H. pylori culture and sensitivity testing were available in 105 
patients. The overall metronidazole resistance rate was 40%. The intent to treat 
eradication rate for patients with metronidazole sensitive strains were significantly 
higher than that for patients with metronidazole resistant strains (85.7% vs 50% 
respectively, p= 0.0001).  
 
 
Ulcer healing 
 The ulcer healing rates (intent-to-treat) were 85.4%, 84.5% and 72% for 
LAM-2W, LAM-1W and LA respectively. There were no significant difference 
among the three groups both in intent-to-treat and per protocol analysis (Table 2).  
 
Side effects  
 The total numbers of events of side effects were 12, 10, and 7 in LAM-2W, 
LAM-1W and LA respectively. The total number of patients experiencing side effects 
were 11 (13.4%), 8 (11.3%) and 7 (9.3%) in groups A, B and C respectively (P= 
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0.72). The common side effects reported included flatulence (3%), epigastric pain 
(3%), diarrhea (1%), nausea (1%), malaise (1%) and dizziness (1%) (Table 3). There 
were no severe side effects and no hospitalization or mortality related to treatment. 
There were no significant differences in the number of patients having side effects 
among the three groups. 
  
Factors affecting ulcer healing 
 After logistic regression analysis, H pylori status at week 6 and size of ulcer 
were shown to affect ulcer healing. The odds ratio for H pylori status was 3.81 (95% 
C.I. : 1.86 – 7.81) and for size of ulcer was 2.13 (95% CI: 1.06 –4.28) (Table 4).   
 
Institution 
The ulcer healing rates varied from the lowest 45.5% in Indonesia  to the 
highest 86.4% in Singapore and Thailand (p=0.012). The ulcer healing rates showed a 
trend of correlation with H. pylori eradication rates, with Indonesia having the lowest 
eradication rate of 63.6% and Thailand having the highest eradication rate of 86.4%, 
but there was no significant difference in H. pylori eradication rate among different 
institutions overall.  Looking at other parameters, there were significant differences in 
age, smoking habit, disease onset and past ulcer history among the 6 regions.   
 The number (%) of patients with metronidazole resistant strains in various 
regions were: Hong Kong and Guangdong 20 (37.7%); China 18 (43.9%); Indonesia 1 
(33.3%); Phillipines 2 (66.7%) and Thailand 1(20%). Hong Kong and Guangdong 
region has a significantly higher eradication rate in patients with metronidazole 
sensitive strains (94%) than patients with metronidazole resistant strains (45%) 
(p=0.0001). For other parts of China, the eradication rate was also higher in patients 
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with metronidazole sensitive strains (74%) than patients with metronidazole resistant 
strains (50%) but did not reach statistical significance (p=0.1). The other countries 
each has less than five cases and were not analyzed here. 
 
   
Discussion 
 H. pylori eradication has become the standard treatment in the management of 
H. pylori-related duodenal ulcer diseases(1). Curing of the infection not only resulted 
in duodenal ulcer healing but significantly reduced the risk of ulcer recurrence (2). 
One of the preferred regime according to the Asia Pacific Consensus report was triple 
therapy which consists of a proton pump inhibitor, clarithromycin and either 
amoxycillin or metronidazole(1). These regimes have been able to attain eradication 
rates of 90% or greater by per protocol analysis and 80% or greater by intention-to-
treat analysis in this region (3-5). Particularly in this part of the World, metronidazole 
resistance of H. pylori is a serious problem. In Hong Kong, we reported a 
metronidazole resistance of 53.5% overall and 38.6% in duodenal ulcer patients (6). 
In other parts of Asia, resistance rates varies from 54% in Malaysia to 95% in Korea 
and Bangladesh. A few studies have shown that the eradication rates using a proton 
pump inhibitor plus amoxicillin and metronidazole were significantly lower for 
metronidazole resistant strains than metronidazole susceptible strains (7-10). The 
eradication rates for resistant strains varied from 45% to 77% while those for 
susceptible strains varied from 90% to 96%.   There are reports stating that a 
clarithromycin-containing triple therapy regime may partly overcome the primary 
resistance to metronidazole (3, 11). Although there are two studies which showed 
comparable eradication rates of around 94% between both metronidazole resistant and 
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susceptible strains (8, 12), majority reported a less favorable eradication rates of 
around 75% in metronidazole resistant strains (13-15). Hence the addition of 
clarithromycin can only increase the eradication rate for metronidazole resistant 
strains by around 10-25%. In this part of the World where clarithromycin may not be 
readily available, it is necessary to test out the efficacy of non-clarithromycin 
containing triple therapy. 
 Our study was a randomized double-blind placebo-controlled trial involving 
fourteen centers throughout five Asian countries. Our controlled study with three 
arms and an adequate number of subjects in each group showed that the eradication 
rates for both lansoprazole-based triple therapies were significantly better than the 
lansoprazole plus amoxicillin dual therapy used. Although there was a slightly higher 
eradication rate of using two week triple therapy, the difference did not reach 
statistical significance. These results were in agreement with previous lansoprazole-
based regimes. In the study by Harford et al, the per protocol eradication rate for 
lansoprazole twice daily plus amoxicillin dual therapy was 57% while an increase of 
lansoprazole to three times daily raised the eradication rate to 67% (16). Our results 
of lansoprazole-based dual therapy were also comparable to those from omeprazole 
plus amoxicillin from recent studies (17,18). In comparing lansoprazole-based triple 
therapy using amoxicillin and metronidazole, we observed an eradication rate of 
around 80% in our two arms, which was slightly better than previous studies. For 
example a study from Misiewicz et al showed a per protocol eradication rate of 
73.5%(11). A similar study showed an intent-to-treat eradication rate of 76%, which 
included 61% in resistant strains and 86.5% in susceptible strains (19). For regimes 
using omeprazole instead of lansoprazole, the results from the MACH 1 study showed 
a per protocol eradication rate of 81.6%, similar to our result (20). 
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 The ulcer healing rates in our study were around 85% for the two triple 
therapy regime but around 70% for the dual therapy regime. After analysis of factors 
affecting ulcer healing, we found that the H. pylori status at week 6 was a crucial 
factor. In our study, the group using dual therapy has a significantly lower H pylori 
eradication rate and therefore affected the rate of ulcer healing. This was in agreement 
with our earlier study that duodenal ulcer healed in 86% in whom H pylori eradication 
was achieved but in 52% in whom eradication failed (21). Other recent studies also 
suggested that eradication of H pylori improved the healing of duodenal ulcer (22,23). 
After logistic regression analysis, apart from H. pylori status at week 6, the ulcer size 
at presentation was also associated with the rate of ulcer healing. This was also in 
agreement with our earlier study and from others (21, 24)      
 
 We observed a similar incidence of side effects among the triple therapy 
groups and the dual therapy group. Most of the side effects were well tolerated. This 
showed that most patients tolerated these two triple therapy regimes well and showed 
also that similar side effects occurred also in treatment with amoxicillin and 
lansoprazole. Other studies showed similar findings to ours (25,26). Hence one week 
or two week lansoprazole-based triple therapy were both well tolerated and 
comparable to two week dual therapy. 
 This study included 14 institutions from 5 different countries in Asia. These 
countries are situated at the proximity to each other. However, there were significant 
differences in patient demographics as well as eradication rate and ulcer healing rates. 
Our study confirmed the significantly lower eradication rate of 50% in patients with 
metronidazole resistant strains than 85.7% in patients with metronidazole sensitive 
strains. Hong Kong and the rest of China have similar prevalence of metronidazole 
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resistance and showed lower eradication rates in patients with metronidazole resistant 
strains. Unfortunately bacterial culture tests were performed in a small subset of 
patients in Indonesia, the Philippines and Thailand. We therefore could not draw any 
conclusion to the effect of prevalence of metronidazole sensitivity on the differences 
in eradication rate and ulcer healing observed in these countries. The difference in 
patient demographics also suggested that more studies need to be done to find out the 
most suitable and cost-effective anti-H. pylori regime in different populations in Asia.  
 In conclusion, one week and two week lansoprazole-based triple therapy 
without clarithromycin have similar efficacy in H. pylori eradication and duodenal 
ulcer healing, and both are significantly better than the lansoprazole plus amoxycillin 
dual therapy. All regimes were safe and well tolerated. The eradication of H pylori 
and initial ulcer size were factors affecting duodenal ulcer healing. Hence the use of 
one week regime of lansoprazole, amoxycillin and metronidazole conforms with the 
recommendation of Asia Pacific Consensus on H pylori. 
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Table 1.   Demographic data of patients 
 
                                                LAM-2W LAM-1W LA  p value 
 
Total number   82  71  75  
Age, (yr)(mean + SD)  47.1 + 14.6 50.0 + 14.1 45.6 + 13.7 0.17 
M:F    66:16  48:23  61:14  0.20 
Smoking (%)   50  38  40  0.42 
Alcohol (%)   35  24  31  0.69 
Coffee (%)   33  35  33  0.67 
Pain score (mean + SD) 1.8 + 0.7 2.3 + 1.0 2.1 + 0.9 0.42 
DU size (mm) (mean + SD) 9.8 + 4.6 9.2 + 3.8 9.0 + 4.2 0.45 
                                                                                                                                    .    
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Outcome of H. pylori eradication and ulcer healing in relation to treatment groups 
 
                                 p value                             .  
 
                                                LAM-2W (A) LAM-1W(B)       LA(C)      Overall      Among 3 gps    Pairwise comparison  
                    A v B    A v C     B v C  
Intention to treat 
    Hp eradication, (%) 68/82 (82.9) 55/71 (77.5) 43/75 (57.3) 166/228 (72.8) 0.001        0.42     0.0008     0.01 
    Ulcer healing, (%)  70/82 (85.4) 60/71 (84.5) 54/75 (72.0) 184/228 (80.7) 0.065             -             -            - 
 
 
Per protocol 
    Hp eradication, (%) 68/82 (82.9) 55/71 (77.5) 43/73 (58.9) 166/226 (73.4) 0.002        0.42     0.0012     0.02 
    Ulcer healing, (%)  70/82 (85.4) 60/71 (84.5) 52/73 (71.2) 182/226 (80.5) 0.051             -             -            - 
                                                                                                                                                                                                                     .       
 
Note: The groups were compared based on a closed testing procedure. If a statistically significant difference  
was detected among the three groups, pairwise comparison were carried out, using the chi-square test without  
correction of continuity. 
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Table 3.  
 
Side effects experienced by patients 
 
    LAM-2W LAM-1W LA  Total             .                     
 
Epigastric pain  3  3  1  7 
Flatulence   3  2  1  6 
Diarrhoea   0  1  2  3 
Malaise   2  1  0  3 
Nausea   0  1  2  3 
Dizziness   1  1  0  2 
Heartburn   1  1  0  2 
Pruritus   1  0  0  1 
Regurgitation   1  0  0  1 
Bloating   0  0  1  1 
 
Total episodes   12  10  7  29 
Total patient, (%)  11 (13.4%) 8 (11.3%) 7 (9.3%) 26 (11.4%)* 
                                                                                                                                              . 
*p = 0.72 (chi-square test) 
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Table 4. 
 
Factors affecting duodenal ulcer healing 
 
Logistic regression analysis 
 
 
Parameter Estimate 
 Model    level   parameter    test 
     estimate s.e.  Wald  df  p-value 
 Constant      -  - 3.42  0.76  20.18  1  0 
   Hp eradication negative   1.33  0.37  13.29  1  0.0003 
   Ulcer size      0.76  0.35    4.56  1  0.033 
 
 
Goodness-of-Fit 
 chi-square   df  p-value       
 
    deviance      17.85  2  0.0001 
 
 
 
Odds Ratio 
   Odds ratio  95% Confidence interval . 
 
Hp Eradication    3.81    1.86 – 7.81 
Ulcer size      2.13    1.06 – 4.28 
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